SUNPHARMA Sun Pharmaceuticals Industries Ltd Product Launches Announcement 2024 - LEQSELVI Update Sun Pharmaceutical Industries presented new data on LEQSELVI (deuruxolitinib) showing ongoing improvement in scalp hair regrowth for alopecia areata treatment at the 2024 Fall Clinical Dermatology Conference, with 68-week study results indicating a SALT response of 76.6%. The data suggest LEQSELVI is a preferred option among patients and clinicians for its efficacy and rapid onset of action..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Sun Pharmaceuticals Industries Ltd